Vanda Pharma Amends 8-K Filing for Financial Statements and Exhibits
Ticker: VNDA · Form: 8-K/A · Filed: Feb 16, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K/A |
| Filed Date | Feb 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits, SEC-filing
TL;DR
**Vanda Pharma just filed an 8-K/A to update financial statements and exhibits from their December 7, 2023 report.**
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K/A on February 16, 2024, amending a previous report from December 7, 2023. This amendment, designated as Amendment No. 1, pertains to Item 9.01, Financial Statements and Exhibits, and was filed under the Securities Exchange Act of 1934. The company, based in Washington, D.C., with IRS Employer Identification No. 03-0491827, operates in the pharmaceutical preparations industry.
Why It Matters
This amendment provides updated or corrected financial statements and exhibits, which are crucial for investors to have accurate and complete information about Vanda Pharmaceuticals Inc.'s financial health and operations.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, typically for corrections or additions, and does not inherently indicate new significant risks.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- December 7, 2023 (date) — Date of earliest event reported
- February 16, 2024 (date) — Filed as of date
- 03-0491827 (null) — IRS Employer Identification No.
- Washington, D.C. (null) — Principal executive offices city
FAQ
What is the purpose of this 8-K/A filing by Vanda Pharmaceuticals Inc.?
This 8-K/A filing is an Amendment No. 1 to a previous Current Report, specifically addressing Item 9.01, Financial Statements and Exhibits, as reported on December 7, 2023.
When was the earliest event reported in the original filing that this amendment refers to?
The earliest event reported in the original filing was December 7, 2023.
What is the full name and location of the registrant?
The registrant is Vanda Pharmaceuticals Inc., with its principal executive offices located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
Under which act of the SEC was this report filed?
This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Vanda Pharmaceuticals Inc.'s Central Index Key (CIK) and Commission File Number?
Vanda Pharmaceuticals Inc.'s Central Index Key (CIK) is 0001347178, and its Commission File Number is 001-34186.
Filing Stats: 710 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-02-16 16:31:12
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Ma
Filing Documents
- d620689d8ka.htm (8-K/A) — 28KB
- d620689dex231.htm (EX-23.1) — 3KB
- d620689dex991.htm (EX-99.1) — 72KB
- d620689dex992.htm (EX-99.2) — 51KB
- d620689dex993.htm (EX-99.3) — 58KB
- 0001193125-24-038517.txt ( ) — 372KB
- vnda-20231207.xsd (EX-101.SCH) — 3KB
- vnda-20231207_lab.xml (EX-101.LAB) — 18KB
- vnda-20231207_pre.xml (EX-101.PRE) — 11KB
- d620689d8ka_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a)
Financial Statements of Business Acquired
Financial Statements of Business Acquired. The audited special purpose abbreviated financial statements for the Acquired Business as of and for the years ended January 1, 2023 and January 2, 2022 and the unaudited special purpose abbreviated financial statements for the Acquired Business as of and for the nine months ended October 1, 2023 and October 2, 2022 are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated in this Item 9.01(a) by reference. (b) Pro Forma Financial Information The unaudited pro forma condensed combined financial statements for the year ended December 31, 2023 giving effect to the acquisition of the Acquired Business are filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated in this Item 9.01(b) by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm. 99.1 Audited Special Purpose Abbreviated Financial Statements for the Acquired Business as of and for the years ended January 1, 2023 and January 2, 2022. 99.2 Unaudited Special Purpose Abbreviated Financial Statements for the Acquired Business as of and for the nine months ended October 1, 2023 and October 2, 2022. 99.3 Unaudited pro forma condensed combined financial information for the year ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 16, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary